New England Journal of Medicine June 1, 2017  Vol. 376 No. 22

New England Journal of Medicine
June 1, 2017  Vol. 376 No. 22

Review Article
The Changing Face of Clinical Trials
Health Policy Trials
Joseph P. Newhouse, Ph.D., and Sharon-Lise T. Normand, Ph.D.
N Engl J Med 2017; 376:2160-2167 June 1, 2017 DOI: 10.1056/NEJMra1602774
Clinical trials are most commonly associated with drugs and devices, but there are notable examples of trials that involve health policy. Many such trials test innovations in the delivery of services, whereas others focus on financial incentives for patients or providers. This review of health policy trials is not meant to be comprehensive; rather, we mainly consider trials of financial incentives because of their relevance to public policy. Trials of different insurance plans may, for example, vary the degree of cost sharing borne by the patient or the scope of covered services, or they may vary the terms of provider reimbursement.

May 25, 2017  Vol. 376 No. 21
Accelerated Approval and Expensive Drugs — A Challenging Combination
Walid F. Gellad, M.D., M.P.H., and Aaron S. Kesselheim, M.D., J.D., M.P.H.
N Engl J Med 2017; 376:2001-2004 May 25, 2017 DOI: 10.1056/NEJMp1700446

Sharing Clinical and Genomic Data on Cancer — The Need for Global Solutions
The Clinical Cancer Genome Task Team of the Global Alliance for Genomics and Health
N Engl J Med 2017; 376:2006-2009 May 25, 2017 DOI: 10.1056/NEJMp1612254